LY231514 500mg/m2 and LY231514 1000mg/m2 in patients with advanced non-small cell lung cancer who were previously treated with prior systemic anti cancer therapy: a randomized phase II trial
Latest Information Update: 11 Feb 2010
At a glance
- Drugs Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 06 Nov 2008 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
- 27 Dec 2007 The expected completion date for this trial is now 1 Dec 2008 according to ClinicalTrials.gov.
- 23 Sep 2007 Survival outcomes were reported at ECCO 2007.